Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1977 2
1979 1
1995 1
1996 2
2001 2
2002 1
2005 2
2006 3
2007 5
2008 2
2009 2
2010 4
2011 4
2012 6
2013 9
2014 5
2015 9
2016 16
2017 12
2018 24
2019 18
2020 15
2021 25
Text availability
Article attribute
Article type
Publication date

Search Results

147 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Marchewka-Bartkowiak
Page 1
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial().
Montemurro F, Delaloge S, Barrios CH, Wuerstlein R, Anton A, Brain E, Hatschek T, Kelly CM, Peña-Murillo C, Yilmaz M, Donica M, Ellis P. Montemurro F, et al. Ann Oncol. 2020 Oct;31(10):1350-1358. doi: 10.1016/j.annonc.2020.06.020. Epub 2020 Jul 5. Ann Oncol. 2020. PMID: 32634611 Free article. Clinical Trial.
Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of patients in small clinical series. PATIENTS AND METHODS: KAMILLA is an ongoing, phase IIIb study of T-DM1 in patients with HER2-positive locally advanced/metastatic breast cancer with prior HER2-t …
Trastuzumab emtansine (T-DM1) has shown potential activity in this subset of patients in small clinical series. PATIENTS AND METHODS: KAM
Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: Primary results from the KAMILLA study cohort 1.
Montemurro F, Ellis P, Anton A, Wuerstlein R, Delaloge S, Bonneterre J, Quenel-Tueux N, Linn SC, Irahara N, Donica M, Lindegger N, Barrios CH. Montemurro F, et al. Eur J Cancer. 2019 Mar;109:92-102. doi: 10.1016/j.ejca.2018.12.022. Epub 2019 Jan 29. Eur J Cancer. 2019. PMID: 30708264 Free article. Clinical Trial.
METHODS: KAMILLA (NCT01702571) is a single-arm, open-label, international, phase IIIb safety study of patients with HER2-positive advanced BC with progression after prior treatment with chemotherapy and a HER2-directed agent for MBC or within 6 months of completing adjuvan …
METHODS: KAMILLA (NCT01702571) is a single-arm, open-label, international, phase IIIb safety study of patients with HER2-positive adv …
Course of recovery from alcoholism.
Venner KL, Matzger H, Forcehimes AA, Moos RH, Feldstein SW, Willenbring ML, Weisner C. Venner KL, et al. Alcohol Clin Exp Res. 2006 Jun;30(6):1079-90. doi: 10.1111/j.1530-0277.2006.00121.x. Alcohol Clin Exp Res. 2006. PMID: 16737468 Free PMC article.
This article represents the proceedings of a symposium at the 2005 Research Society on Alcoholism meeting in Santa Barbara, California, organized and chaired by Kamilla L. Venner. This symposium integrated current empirical research on the course of recovery from alcoholis …
This article represents the proceedings of a symposium at the 2005 Research Society on Alcoholism meeting in Santa Barbara, California, orga …
147 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page